Horizon scan of nanomedicinal products

Nanomedicine

Volumn 10, Issue 10, 2015, Pages 1599-1608

  Noorlander, Cornelle W ^a   Kooi, Myrna W ^a   Oomen, Agnes G ^a   Park, Margriet V D Z ^a   Vandebriel, Rob J ^a   Geertsma, Robert E ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

horizon scan; nanodrugs; nanomedicinal products; nanomedicine; nanotechnology; therapeutics

Indexed keywords

LIPOSOME; NANOCONJUGATE; POLYMER;

ARTICLE; CANCER THERAPY; CARDIOVASCULAR DISEASE; DRUG APPROVAL; ENDOCRINE DISEASE; EUROPE; FOOD AND DRUG ADMINISTRATION; FRANCE; GERMANY; INFECTION; INTERNET; IRON DEFICIENCY; KIDNEY DISEASE; MOLECULAR IMAGING; NANOMEDICINE; NETHERLANDS; NEUROLOGIC DISEASE; PARTICLE SIZE; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; SCIENTIFIC LITERATURE; SYSTEMATIC REVIEW; UNITED KINGDOM; FORECASTING; HUMAN; TRENDS;

FORECASTING; HUMANS; NANOMEDICINE;

EID: 84930162991     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.15.21     Document Type: Article

References (38)

1. Rizzo LY, Theek B, Storm G, Kiessling F, Lammers T. Recent progress in nanomedicine: therapeutic, diagnostic and theranostic applications. Curr. Opin. Biotechnol. 24(6), 1159-1166 (2013
2. Murthy SK. Nanoparticles in modern medicine: state of the art and future challenges. Int. J. Nanomedicine 2(2), 129-141 (2007
3. Kim BY, Rutka JT, Chan WC. Nanomedicine. N. Engl. J. Med. 363(25), 2434-43 (2010
4. Geertsma RE, Herberts CA, Brouwer N. Nanotechnology in medical applications. In: Nanotechnology in Perspective: Risks to Man and the Environment. van Zijverden M, Sips AJAM (Eds). RIVM Report 601785003/2009. RIVM, Bilthoven, The Netherlands (2009
5. Thorley AJ, Tetley TD. New perspectives in nanomedicine. Pharmacol. Therapeut. 140(2), 176-185 (2013
6. Duncan R, Gaspar R. Nanomedicine(s) under the microscope. Mol. Pharm. 8(6), 2101-2141 (2011
7. Deshpande PP, Biswas S, Torchilin VP. Current trends in the use of liposomes for tumor targeting. Nanomedicine (Lond.) 8(9), 1509-1528 (2013
8. Jhaveri AM, Torchilin VP. Multifunctional polymeric micelles for delivery of drugs and siRNA. Front. Pharmacol. 5, 77 (2014
9. Messina PV, Besada-Porto JM, Ruso JM. Self-Assembly drugs: from micelles to nanomedicine. Curr. Top. Med. Chem. 14(5), 555-571 (2014
10. Chen X, Schluesener HJ. Nanosilver: a nanoproduct in medical application. Toxicol. Lett. 176(1), 1-12 (2008
11. Ge L, Li Q, Wang M, Ouyang J, Li X, Xing MM. Nanosilver particles in medical applications: synthesis, performance, and toxicity. Int. J. Nanomedicine 9, 2399-2407 (2014
12. Hilger I, Kaiser WA. Iron oxide-based nanostructures for MRI and magnetic hyperthermia. Nanomedicine (Lond.) 7(9), 1443-1459 (2012
13. Laurent S, Saei AA, Behzadi S, Panahifar A, Mahmoudi M. Superparamagnetic iron oxide nanoparticles for delivery of therapeutic agents: opportunities and challenges. Expert Opin. Drug Deliv. 1-22 (2014
14. Onoue S, Yamada S, Chan HK. Nanodrugs: pharmacokinetics and safety. Int. J. Nanomedicine 9, 1025-1037 (2014
15. Kedar U, Phutane P, Shidhaye S, Kadam V. Advances in polymeric micelles for drug delivery and tumor targeting. Nanomedicine 6(6), 714-729 (2010
16. Li W, Feng S, Guo Y. Tailoring polymeric micelles to optimize delivery to solid tumors. Nanomedicine (Lond.) 7(8), 1235-1252 (2012
17. Alyautdin R, Khalin I, Nafeeza MI, Haron MH, Kuznetsov D. Nanoscale drug delivery systems and the blood-brain barrier. Int. J. Nanomedicine 9, 795-811 (2014
18. Ehmann F, Sakai-Kato K, Duncan R, et al. Next-generation nanomedicines and nanosimilars: EU regulators' initiatives relating to the development and evaluation of nanomedicines. Nanomedicine (Lond.) 8(5), 849-856 (2013
19. Crist RM, Grossman JH, Patri AK, et al. Common pitfalls in nanotechnology: lessons learned from NCI's Nanotechnology Characterization Laboratory. Integr. Biol. (Camb.) 5(1), 66-73 (2013
20. EFSA. Guidance on the risk assessment of the application of nanoscience and 33 nanotechnologies in the food and feed chain. EFSA J. 9, 2140 (2011
21. SCCS, Guidance on the safety assessment of nanomaterials in cosmetics. SCCS, 14 European Commission, Brussels, Belgium (2012). http://ec.europa.eu
22. EMA. http://www.ema.europa.eu
23. Etheridge ML, Campbell SA, Erdman AG, Haynes CL, Wolf SM, McCullough J. The big picture on nanomedicine: the state of investigational and approved nanomedicine products. Nanomedicine 9(1), 1-14 (2013
24. Health Canada. http://www.hc-sc.gc.ca/dhp-mps/nano-eng.php
25. EU, Commission recommendation of 18 October 2011 on the definition of nanomaterial (2011/696/EU). OJEU L 275, 38-40 (2011
26. EEM. Reflection paper on nanotechnology-based medicinal products for Human Use. Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency (EMEA), London, UK, Document No. EMEA/ CHMP/79769/2006 (2006
27. US FDA. http://www.fda.gov
28. Health Canada. http://www.hc-sc.gc.ca/sr-sr/pubs/nano/pol-eng.php
29. Nano World Cancer Day. http://www.nanoworldcancerday.eu/countries/finland/
30. BCC. http://www.etp-nanomedicine.eu
31. Wagner V, Dullaart A, Bock AK, Zweck A. The emerging nanomedicine landscape. Nat. Biotechnol. 24(10), 1211-1217 (2006
32. EETP. Contribution of Nanomedicine to Horizon 2020 (2013
33. Hafner A, Lovric J, Lakos GP, Pepic I. Nanotherapeutics in the EU: an overview on current state and future directions. Int. J. Nanomedicine 9, 1005-1023 (2014
34. Schutz CA, Juillerat-Jeanneret L, Mueller H, Lynch I, Riediker M. Therapeutic nanoparticles in clinics and under clinical evaluation. Nanomedicine (Lond.) 8(3), 449-467 (2013
35. US FDA. http://www.pqri.org
36. Niidome T, Yamagata M, Okamoto Y, et al. Niidome, PEG-modified gold nanorods with a stealth character for in vivo applications. J. Control. Release 114(3), 343-347 (2006
37. Lankveld DP, Rayavarapu RG, Krystek P, et al. Blood clearance and tissue distribution of PEGylated and non-PEGylated gold nanorods after intravenous administration in rats. Nanomedicine (Lond.) 6(2), 339-349 (2011
38. Barenholz Y. Doxil®-The first FDA-Approved nano-drug: lessons learned. J. Control Release 160(2), 117-134 (2012